Piperine–Chlorogenic Acid Hybrid Inhibits the Proliferation of the SK-MEL-147 Melanoma Cells by Modulating Mitotic Kinases
Pharmaceuticals · 19.01.2023 · 16 (2) · 145
DOI: 10.3390/ph16020145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 19.01.2023. Verfasst von Carolina Girotto Pressete und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: INCT-INOFAR Program (CNPq, Brazil), FAPEMIG (Brazil), CNPq (Brazil).
Abstract (Originalsprache)
Melanoma is considered the most aggressive form of skin cancer, showing high metastatic potential and persistent high mortality rates despite the introduction of immunotherapy and targeted therapies. Thus, it is important to identify new drug candidates for melanoma. The design of hybrid molecules, with different pharmacophore fragments combined in the same scaffold, is an interesting strategy for obtaining new multi-target and more effective anticancer drugs. We designed nine hybrid compounds bearing piperine and chlorogenic acid pharmacophoric groups and evaluated their antitumoral potential on melanoma cells with distinct mutational profiles SK-MEL-147, CHL-1 and WM1366. We identified the compound named PQM-277 (3a) to be the most cytotoxic one, inhibiting mitosis progression and promoting an accumulation of cells in pro-metaphase and metaphase by altering the expression of genes that govern G2/M transition and mitosis onset. Compound 3a downregulated FOXM1, CCNB1, CDK1, AURKA, AURKB, and PLK1, and upregulated CDKN1A. Molecular docking showed that 3a could interact with the CUL1-RBX1 complex, which activity is necessary to trigger molecular events essential for FOXM1 transactivation and, in turn, G2/M gene expression. In addition, compound 3a effectively induced apoptosis by increasing BAX/BCL2 ratio. Our findings demonstrate that 3a is an important antitumor candidate prototype and support further investigations to evaluate its potential for melanoma treatment, especially for refractory cases to BRAF/MEK inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.
- Institute of Chemistry, Laboratory of Research in Medicinal Chemistry, Federal University of Alfenas, Alfenas 37133-840, MG, Brazil.
- Department of Clinic and Surgery, School of Dentistry, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.
ORCID-Profile: Claudio Viegas
Förderung
- INCT-INOFAR Program (CNPq, Brazil)
- FAPEMIG (Brazil)
- CNPq (Brazil)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brazil (CAPES)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brazil (CAPES)
Zitieren
APA
Pressete, C. G., Viegas, F. P. D., Campos, T. G., Caixeta, E. S., Hanemann, J. A. C., Ferreira-Silva, G. Á., Zavan, B., Aissa, A. F., Miyazawa, M., Viegas, C., & Ionta, M. (2023). Piperine–Chlorogenic Acid Hybrid Inhibits the Proliferation of the SK-MEL-147 Melanoma Cells by Modulating Mitotic Kinases. Pharmaceuticals, 16(2), 145. https://doi.org/10.3390/ph16020145
Vancouver
Pressete CG, Viegas FPD, Campos TG, Caixeta ES, Hanemann JAC, Ferreira-Silva GÁ, et al. Piperine–Chlorogenic Acid Hybrid Inhibits the Proliferation of the SK-MEL-147 Melanoma Cells by Modulating Mitotic Kinases. Pharmaceuticals. 2023;16(2):145. doi:10.3390/ph16020145
BibTeX
@article{Pressete2023,
author = {Pressete, Carolina Girotto and Viegas, Flávia Pereira Dias and Campos, Thâmara Gaspar and Caixeta, Ester Siqueira and Hanemann, João Adolfo Costa and Ferreira-Silva, Guilherme Álvaro and Zavan, Bruno and Aissa, Alexandre Ferro and Miyazawa, Marta and Viegas, Claudio and Ionta, Marisa},
title = {Piperine–Chlorogenic Acid Hybrid Inhibits the Proliferation of the SK-MEL-147 Melanoma Cells by Modulating Mitotic Kinases},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {2},
pages = {145},
doi = {10.3390/ph16020145}
}
EUVIMED